XML 92 R77.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingencies (Details)
1 Months Ended 9 Months Ended 12 Months Ended
Sep. 26, 2023
May 01, 2023
USD ($)
shares
Mar. 15, 2023
May 14, 2021
USD ($)
Apr. 14, 2021
Apr. 14, 2021
Apr. 13, 2020
Apr. 13, 2020
Feb. 11, 2020
USD ($)
Jun. 21, 2019
USD ($)
Jun. 21, 2019
USD ($)
Jan. 01, 2019
USD ($)
Sep. 12, 2018
USD ($)
Sep. 12, 2018
USD ($)
Apr. 30, 2020
Jan. 31, 2019
USD ($)
Sep. 30, 2023
shares
Dec. 31, 2022
shares
Sep. 19, 2023
USD ($)
Jul. 31, 2023
USD ($)
Jul. 05, 2022
USD ($)
Jul. 26, 2021
USD ($)
Commitments and Contingencies (Details) [Line Items]                                            
Damage value                 $ 2,861,401.66       $ 761,401.66 $ 761,401.66   $ 2,100,000            
Unpaid wages                     $ 30,429                      
Payment amount                                           $ 67,125.83
Award grants (in Shares) | shares                                 585,000          
EDI International, PC [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Unpaid wages                   $ 30,428.71                        
Employment Agreement Paul Gavin [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Description of commitments                             provide for an annual base salary of $400,000, provide for a performance bonus structure for a bonus of up to 50% of base salary upon the Company’s achievement of $2,000,000 EBITDA and additional performance bonus payments for the achievement of EBITDA in excess of $2,000,000 based on a percentage of the incremental increase in EBITDA (ranging from 10% of the incremental increase in EBITDA if the Company achieves over $2,000,000 and up to $7,000,000 in EBITDA, 8% of the incremental increase in EBITDA if the Company achieves over $7,000,000 and up to $12,000,000 in EBITDA and 3% of the incremental increase in EBITDA over $12,000,000), provide for a profits-based additional bonus of up to $250,000 in certain limited circumstances, and provide for one (1) year severance, plus a pro-rated amount of any unpaid bonus earned by him during the year as verified by the Company’s principal financial officer, if Mr. Galvin is terminated without cause. At the Company’s option, up to fifty (50%) percent of the EBITDA performance bonuses may be paid in restricted stock units if then available for grant under the Company’s Stock Incentive Plan. All other terms of the employment agreement remain in full force and effect.              
Payment of base annual salary                                         $ 500,000  
Employment Agreement [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Description of commitments                             provide for an annual base salary of $400,000 provide for a performance bonus structure for a bonus of up to 50% of base salary upon the Company’s achievement of $2,000,000 EBITDA and additional performance bonus payments for the achievement of EBITDA in excess of $2,000,000 based on a percentage of the incremental increase in EBITDA (ranging from 10% of the incremental increase in EBITDA if the Company achieves over $2,000,000 and up to $7,000,000 in EBITDA, 8% of the incremental increase in EBITDA if the Company achieves over $7,000,000 and up to $12,000,000 in EBITDA and 3% of the incremental increase in EBITDA over $12,000,000), provide for a profits-based additional bonus of up to $250,000 in certain limited circumstances, and provide for one (1) year severance, plus a pro-rated amount of any unpaid bonus earned by him during the year as verified by the Company’s principal financial officer, if Mr. Galvin is terminated without cause. At the Company’s option, up to fifty (50%) percent of the EBITDA performance bonuses may be paid in restricted stock units if then available for grant under the Company’s Incentive Plan.              
HOLA Defendants [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Amount claimed             7                              
Teton [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Damage value                       $ 2,100,000                    
Osang Healthcare Company Ltd [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Description of commitments           The Company has asserted that Osang materially breached a certain Managed Supply Agreement (“MSA”) entered into between the parties on October 12, 2020, pursuant to which the Company received on consignment two million (2,000,000) units of Osang’s “Genefinder Plus RealAmp Covid-19 PCR Test” (the “Covid-19 Test”) for domestic and international distribution. The Company has also asserted that Osang breached the covenant of good faith and fair dealing, fraudulently induced it to enter into the MSA, and violated §349 of the New York General Business Law’s prohibition of deceptive business practices.                                
Shaw Stockholders [Member] | Settlement Agreement [Member] | Pending Litigation [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Number of shareholders     2                                      
Expiration period of irrevocable proxy 3 months                                          
Amount paid $10,000                                          
Expiration date of the irrevocable proxies 45 days                                          
HOLA Defendants [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Amount claimed               7                            
Osang Healthcare Company Ltd [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Description of commitments         The Company has asserted that Osang materially breached a certain Managed Supply Agreement (“MSA”) entered into between the parties on October 12, 2020, pursuant to which the Company received on consignment two million (2,000,000) units of Osang’s “Genefinder Plus RealAmp Covid-19 PCR Test” (the “Covid-19 Test”) for domestic and international distribution. The Company has also asserted that Osang breached the covenant of good faith and fair dealing, fraudulently induced it to enter into the MSA, and violated §349 of the New York General Business Law’s prohibition of deceptive business practices.                                  
Osang Healthcare Company Ltd [Member] | EDI International, PC [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Damage value       $ 67,125.83                                    
Chief Executive Officer [Member] | Employment Agreement [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Payment of base annual salary                                     $ 750,000   $ 500,000  
Chief Financial Officer [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Annual base salary   $ 250,000                                        
Percentage of base salary   20.00%                                        
Chief Financial Officer [Member] | Employment Agreement [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Adjusted salary                                       $ 300,000    
Restricted Stock Units (RSUs) [Member]                                            
Commitments and Contingencies (Details) [Line Items]                                            
Award grants (in Shares) | shares   60,000                               1,125,000        
Vesting period   18 years